Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CRM
IHD
TabrectaⓇ - Met Inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT04427072 (CINC280A2301)
Non-small cell lung cancer
Phase 3
90
Progression free survival (PFS) per blinded independent review committee (BIRC)
using RECIST v1.1
Arms Intervention
Target Patients
Read-out Milesstone(s)
Arm 1: 400mg of capmatinib tablets administered orally twice daily
Arm 2: Docetaxel 75 mg/m2 by intravenous infusion every 21 days
Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or
Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation
(METAex14).
Primary 2022
Final: 2024
Publication
TBD
114 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation